Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone

Documenti analoghi

• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
  di: Paludo, Jonas, et al.
  Pubblicazione: (2017)
• Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
  di: Laubach, Jacob P., et al.
  Pubblicazione: (2021)
• A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
  di: Richardson, Paul G., et al.
  Pubblicazione: (2014)
• Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
  di: Richardson, P G, et al.
  Pubblicazione: (2017)
• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.
  di: Attal, Michel, et al.
  Pubblicazione: (2017)